AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3887977 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ranitidine
Number of subjects: 120
Study 3887977 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg cimetidine
Number of subjects: 120
Study 30793466 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg/d
Number of subjects: 103
Study 30793466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (halved doses of valsartan and benazepril)
Number of subjects: 103
Study 30793466 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg/d
Number of subjects: 103
Study 29587710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer programme
Number of subjects: 2907
Study 26853239 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (20-g divided into two doses before and after strength training)
Number of subjects: 11
Study 26853239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 24970519 — intervention group
Group type: EXPERIMENTAL
Intervention: Video modelling
Number of subjects: 180
Study 24970519 — intervention group
Group type: COMPARATOR
Intervention: Control video (oral hygiene instruction)
Number of subjects: 180
Study 22357964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate for 4 weeks in DIO C57Bl/6 mice
Number of subjects: 16
Study 22357964 — intervention group
Group type: COMPARATOR
Intervention: Salsalate for 2 weeks in a randomized double-blind placebo-controlled crossover study in men
Number of subjects: 16
Study 22357964 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro salicylate treatment
Number of subjects: 16
Study 22357964 — intervention group
Group type: EXPERIMENTAL
Intervention: DIO 11β‐HSD1‐deficient mice
Number of subjects: 16
Study 20378005 — intervention group
Group type: EXPERIMENTAL
Intervention: NiOH treatment (0.3ng to 1.5 microg/week for 4 months, followed by 1.5 microg/week for 12 months)
Number of subjects: 36
Study 20378005 — intervention group
Group type: EXPERIMENTAL
Intervention: NiOH treatment
Number of subjects: 36
Study 20378005 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-Ni diet alone)
Number of subjects: 36
Study 17336970 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B preparation
Number of subjects: 102
Study 17336970 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 102
Study 17336970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin B preparation and metformin
Number of subjects: 102
Study 17336970 — intervention group
Group type: COMPARATOR
Intervention: Control (standard infertility treatment only)
Number of subjects: 102
Study 15632253 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 15632253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12486516 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1%
Number of subjects: 89
Study 12486516 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 89
Study 10488254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bier block solution with 2 mg of morphine sulfate
Number of subjects: 30
Study 10488254 — intervention group
Group type: COMPARATOR
Intervention: Standard Bier block solution without morphine sulfate
Number of subjects: 30
Study 7659265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg die
Number of subjects: 45
Study 7659265 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg die
Number of subjects: 45
Study 7659265 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg die
Number of subjects: 45
Study 2504119 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (0.15 mg/kg/h after a loading dose of 2 mg/kg)
Number of subjects: 30
Study 2504119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2504119 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 30
Study 30100278 — intervention group
Group type: EXPERIMENTAL
Intervention: Crunch exercise with Ki-hap group (CKG)
Number of subjects: 90
Study 30100278 — intervention group
Group type: EXPERIMENTAL
Intervention: Crunch exercise with Ki-hap and verbal encouragement group (CKVG)
Number of subjects: 90
Study 30100278 — intervention group
Group type: COMPARATOR
Intervention: Crunch only exercise group (CG)
Number of subjects: 90
Study 28077412 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) plus best medical treatment (BMT)
Number of subjects: 100
Study 28077412 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 100
Study 25604371 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Number of subjects: 130
Study 23168014 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (125mg bid)
Number of subjects: 36
Study 23168014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21044148 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 77
Study 21044148 — intervention group
Group type: COMPARATOR
Intervention: Delayed pushing (2 hours)
Number of subjects: 77
Study 17466263 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced guilt
Number of subjects: 0
Study 17217741 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (INR 2.0 to 3.0)
Number of subjects: 335
Study 14725326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajoene (0.5% gel)
Number of subjects: 37
Study 14725326 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (1% cream)
Number of subjects: 37
Study 10890481 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion plus transesophageal atrial pacing (group 2, 17 patients)
Number of subjects: 36
Study 10890481 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine infusion (group 1, 19 patients)
Number of subjects: 36
Study 8844121 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick
Number of subjects: 15
Study 8844121 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis (0.13 mA for 10 s)
Number of subjects: 15
Study 8844121 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis (2.0 mA for 10 s)
Number of subjects: 15
Study 1513113 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45
Study 1513113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injections
Number of subjects: 45
Study 1513113 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections a day
Number of subjects: 45
Study 1513113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HbA1 less than 10%
Number of subjects: 45
Study 1513113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HbA1 greater than 10%
Number of subjects: 45
Study 6422538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg twice daily
Number of subjects: 15
Study 6422538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 200 mg four times daily
Number of subjects: 15
Study 6422538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6422538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine, 400 mg twice daily
Number of subjects: 15
Study 6422538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine, 200 mg four times daily
Number of subjects: 15
Study 31444162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg concizumab (with potential escalation to 0.20 and 0.25 mg/kg)
Number of subjects: 53
Study 31444162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg concizumab
Number of subjects: 53
Study 28125093 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) supplementation at a dose of 5 μg kg-1 day-1
Number of subjects: 51
Study 28125093 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no L-T4 supplementation)
Number of subjects: 51
Study 27085466 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology lens wear (SiHCLW group)
Number of subjects: 22
Study 27085466 — intervention group
Group type: COMPARATOR
Intervention: Control group (NCLW)
Number of subjects: 22
Study 24591332 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically adjusted drug treatment (n=10)
Number of subjects: 19
Study 24591332 — intervention group
Group type: COMPARATOR
Intervention: Renal sympathetic denervation (RDN) (n=9)
Number of subjects: 19
Study 24591332 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 19
Study 21739090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (Group B)
Number of subjects: 45
Study 21739090 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (Group L)
Number of subjects: 45
Study 21739090 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 45
Study 19410958 — intervention group
Group type: EXPERIMENTAL
Intervention: FL‐41‐tinted lenses
Number of subjects: 30
Study 19410958 — intervention group
Group type: COMPARATOR
Intervention: Gray‐tinted lenses
Number of subjects: 30
Study 19410958 — intervention group
Group type: COMPARATOR
Intervention: Rose-tinted lenses
Number of subjects: 30
Study 16800833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 70
Study 16800833 — intervention group
Group type: COMPARATOR
Intervention: mock TENS
Number of subjects: 70
Study 14989285 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 10754619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg/kg
Number of subjects: 165
Study 10754619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 2.0 mg/kg
Number of subjects: 165
Study 10754619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.0-2.0 mg/kg
Number of subjects: 165
Study 10754619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium (various doses)
Number of subjects: 165
Study 10754619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 165
Study 8731516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine challenge test (60 mg)
Number of subjects: 83
Study 1457116 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 250 micrograms/ml
Number of subjects: 90
Study 1457116 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg/ml
Number of subjects: 90
Study 1457116 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 10 mg/ml
Number of subjects: 90
Study 3889027 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (SC) therapy
Number of subjects: 100
Study 3889027 — intervention group
Group type: COMPARATOR
Intervention: Referred Care (RC)
Number of subjects: 100
Study 30624175 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome profiles generated by 16S rRNA gene sequence analysis and targeted nanopore sequencing
Number of subjects: 28
Study 30624175 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical infection observed in DFUs
Number of subjects: 28
Study 30624175 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal profiling of microbiome
Number of subjects: 28
Study 30624175 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of complex communities in DFUs
Number of subjects: 28
Study 29422155 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence education programme (six-group discussion sessions)
Number of subjects: 47
Study 29422155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study 26762334 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain cognitive training
Number of subjects: 70
Study 26762334 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-domain cognitive training
Number of subjects: 70
Study 26762334 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (both multi-domain and single-domain)
Number of subjects: 70
Study 24973911 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) program for treating depression following CABG surgery
Number of subjects: 189
Study 24973911 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 189
Study 22417870 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2+ve tumors (IHC 3+ and/or FISH-amplified)
Number of subjects: 448
Study 22417870 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2‐ve tumors (ER+ve and ER‐ve combined)
Number of subjects: 448
Study 22417870 — intervention group
Group type: EXPERIMENTAL
Intervention: ER+veHER2‐ve subgroup
Number of subjects: 448
Study 22417870 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC-detected ER in ABC
Number of subjects: 448
Study 22417870 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest levels of ER and HER2 RNA levels within the ER+veHER2‐ve subgroup
Number of subjects: 448
Study 19008073 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic-numeric scale
Number of subjects: 96
Study 19008073 — intervention group
Group type: COMPARATOR
Intervention: Text-anchored scale
Number of subjects: 96
Study 17986908 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention consisting of walking, strength, flexibility, and balance training supplemented with behavioral skills training modules, with a phased schedule (3x wk(‐1) for weeks 1-8, 2x wk(‐1) for weeks 9-24, and 1x wk(‐1) for weeks 25 to end of trial)
Number of subjects: 424
Study 17986908 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention with > or = 150 min x wk(‐1) of moderate activity
Number of subjects: 424
Study 17986908 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based attendance during PA intervention
Number of subjects: 424
Study 17986908 — intervention group
Group type: COMPARATOR
Intervention: Health Education Control (SA) consisting of weekly workshops transitioning to monthly
Number of subjects: 424
Study 16617391 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐ioflupane administration (110‐185 MBq/70 kg); thyroid blocking with 120 mg potassium iodide before and after injection.
Number of subjects: 16
Study 16617391 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐ioflupane administration; whole-body scans at 15 min and 2-3 h post-injection.
Number of subjects: 16
Study 16617391 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain SPET scans performed 3-5 h after (123)I‐ioflupane administration.
Number of subjects: 16
Study 16617391 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual examination of morphology of the nigrostriatum (NS) area.
Number of subjects: 16
Study 16617391 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical follow-up after l‐DOPA treatment for 7 months.
Number of subjects: 16
Study 14551174 — intervention group
Group type: EXPERIMENTAL
Intervention: eplerenone 50 mg qd (increased to 100 mg qd if needed)
Number of subjects: 341
Study 14551174 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 341
Study 10958766 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally exhaled nitric oxide (ENO)
Number of subjects: 74
Study 10958766 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 74
Study 8793612 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg (CAP, n = 24)
Number of subjects: 47
Study 8793612 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg plus hydrochlorothiazide 12.5 mg (COR, n = 23)
Number of subjects: 47
Study 8793612 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg (CAP)
Number of subjects: 47
Study 8793612 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg plus hydrochlorothiazide 12.5 mg (COR)
Number of subjects: 47
Study 1451119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 10
Study 6375286 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg daily
Number of subjects: 32
Study 6375286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31945300 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid 5 mg/kg daily for 7 days
Number of subjects: 59
Study 31945300 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 10 mg/kg daily for 7 days
Number of subjects: 59
Study 31945300 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 15 mg/kg daily for 7 days
Number of subjects: 59
Study 28923787 — intervention group
Group type: EXPERIMENTAL
Intervention: BuMA Supreme SES
Number of subjects: 170
Study 28923787 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 170
Study 27189028 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased mean arterial pressure (70-80 mmHg) during cardiopulmonary bypass
Number of subjects: 210
Study 27189028 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (mean arterial pressure 40-50 mmHg) during cardiopulmonary bypass
Number of subjects: 210
Study 23742222 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (10-week program, 3 sessions per week, 30-40 min treadmill exercise at 55-65% peak heart rate)
Number of subjects: 20
Study 22483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalation to the entire primary tumour (arm A)
Number of subjects: 20
Study 22483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalation to the high FDG uptake region inside the primary tumour (arm B)
Number of subjects: 20
Study 22483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalation to the primary tumour (arm A)
Number of subjects: 20
Study 22483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalation to the boost region
Number of subjects: 20
Study 22483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-limiting constraints
Number of subjects: 20
Study 20211036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enteral nutrition (EN) with parenteral nutrition (PN)
Number of subjects: 0
Study 20211036 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PN) alone
Number of subjects: 0
Study 18540460 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy with crystalloidal solutions
Number of subjects: 0
Study 18540460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of crystalloidal solutions and a colloidal agent in a 1:1 ratio
Number of subjects: 0
Study 18540460 — intervention group
Group type: COMPARATOR
Intervention: Infusion therapy with physiological sodium chloride
Number of subjects: 0
Study 15763449 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic asthma
Number of subjects: 23
Study 15763449 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-allergic asthma
Number of subjects: 23
Study 15763449 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 12444337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ointment (calcipotriol/betamethasone dipropionate)
Number of subjects: 1603
Study 12444337 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment
Number of subjects: 1603
Study 12444337 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol ointment
Number of subjects: 1603
Study 12444337 — intervention group
Group type: COMPARATOR
Intervention: Ointment vehicle
Number of subjects: 1603
Study 12444337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ointment
Number of subjects: 1603
Study 12444337 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 1603
Study 12444337 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 1603
Study 10522983 — intervention group
Group type: EXPERIMENTAL
Intervention: High isoflavone (high‐iso) diet
Number of subjects: 18
Study 10522983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low isoflavone (low‐iso) diet
Number of subjects: 18
Study 10522983 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18
Study 8540720 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice a day
Number of subjects: 15
Study 8540720 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine twice a day
Number of subjects: 15
Study 8540720 — intervention group
Group type: COMPARATOR
Intervention: No ranitidine
Number of subjects: 15
Study 1780078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate (200 mg/die, 1 tablet in the morning and evening)
Number of subjects: 40
Study 1780078 — intervention group
Group type: COMPARATOR
Intervention: Sulodexide (500 ULS/die, 1 capsule in the morning and evening)
Number of subjects: 40
Study 6112387 — intervention group
Group type: EXPERIMENTAL
Intervention: A single dose of 300 mg aspirin taken 14 h preoperatively
Number of subjects: 68
Study 6112387 — intervention group
Group type: EXPERIMENTAL
Intervention: A single dose of 81 mg aspirin taken 14 h preoperatively
Number of subjects: 68
Study 6112387 — intervention group
Group type: EXPERIMENTAL
Intervention: A single dose of 40 mg aspirin taken 14 h preoperatively
Number of subjects: 68
Study 6112387 — intervention group
Group type: EXPERIMENTAL
Intervention: A single dose of 300 mg aspirin
Number of subjects: 68
Study 6112387 — intervention group
Group type: EXPERIMENTAL
Intervention: A single dose of 40 mg aspirin
Number of subjects: 68
Study 31631500 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM resin composite inlay (Lava Ultimate)
Number of subjects: 44
Study 31631500 — intervention group
Group type: COMPARATOR
Intervention: Direct resin composite (Clearfil Majesty Posterior)
Number of subjects: 44
Study 28402747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg orally
Number of subjects: 131
Study 28402747 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m2 days 1, 8, and 15 every 28 days)
Number of subjects: 131
Study 24878589 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm support (AS) training combined with computerized exercises
Number of subjects: 70
Study 24878589 — intervention group
Group type: COMPARATOR
Intervention: Conventional reach training (CON)
Number of subjects: 70
Study 23175270 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 20627
Study 23175270 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology with computer-assisted imaging technology (LBC/CAS)
Number of subjects: 20627
Study 23175270 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology (CC)
Number of subjects: 20627